Sunwise Clinical Research — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$513,196	45
2024	Research	$520,135	41
2023	Research	$174,762	11
2022	Research	$159,189	13

Breakdown

Who paid Research payments · program years 2022–2025

Sanofi US Services Inc. $463,739 30 payments
Merck Sharp & Dohme Corporation $274,010 7 payments
Axsome Therapeutics, Inc. $222,520 12 payments
AbbVie, Inc. $126,630 35 payments
Janssen Research & Development, LLC $109,395 12 payments
ITI, Inc. $92,361 6 payments
E.R. Squibb & Sons, L.L.C. $73,693 6 payments
Pfizer Inc. $4,935 2 payments

Studies the money was for Research payments · program years 2022–2025

A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $262,170 5 payments
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms $222,520 12 payments
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD $186,164 9 payments
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis $164,858 11 payments
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment $92,361 6 payments
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an $82,334 7 payments
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $63,129 5 payments
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) $49,588 5 payments
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia $47,451 2 payments
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $43,778 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.